Lupin Acquires US Generics Giant Gavis For A Whopping $880 Million

Lupin Ltd, India's fourth-largest pharmaceutical company, is set to acquire New Jersey-based Gavis Pharmaceuticals LLC and its affiliate Novel Laboratories Inc. in a deal valued at $880 million (approximately ₹5,600 crore). This strategic move aims to bolster Lupin's footprint in the US generics market.

Lupin stated to the BSE, “the acquisition broadens Lupin’s pipeline in dermatology, controlled substance products and other high-value and niche generics.” Mumbai-based Lupin is looking to strengthen its foothold in the US market, where its sales dropped by 31% year-on-year to $180 million in the April-June period, contributing to a 16% decline in net profit to ₹525 crore. Additionally, the company reported a 6% decrease in sales, totaling ₹3,070 crore for the quarter ending June 30.

Lupin stated that Gavis, a closely held company, achieved sales of $96 million in the last fiscal year and employs over 250 people in New Jersey. Specializing in pharmaceutical development, manufacturing, and distribution, Gavis's New Jersey facility will soon operate as Lupin's inaugural manufacturing site in the United States, according to the statement. Lupin's acquisition values Gavis at approximately nine times its annual sales.

Moreover, Gavis currently has 66 abbreviated new drug applications awaiting approval from the US Food and Drug Administration (FDA), collectively representing a potential market value of $9 billion. Additionally, Gavis boasts a pipeline of over 65 products under development, which Lupin will gain access to through this acquisition.